Mirum Pharmaceuticals, Inc. - common stock (MIRM) News
Filter MIRM News Items
MIRM News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MIRM News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest MIRM News From Around the Web
Below are the latest news stories about MIRUM PHARMACEUTICALS INC that investors may wish to consider to help them evaluate MIRM as an investment opportunity.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)FOSTER CITY, Calif., January 10, 2025--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceFOSTER CITY, Calif., January 06, 2025--Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Path To ProfitabilityMirum Pharmaceuticals, Inc. ( NASDAQ:MIRM ) is possibly approaching a major achievement in its business, so we would... |
Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report?Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Mirum Pharmaceuticals price target raised to $74 from $69 at JMP SecuritiesJMP Securities raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $74 from $69 and keeps an Outperform rating on the shares as part of a broader note on Biotechnology. The firm highlighted key upcoming catalysts for its coverage universe over the next 12 months, ahead of what is shaping up to be a “busy” 2025, and noted that it still has several events expected between now and the end of the year which could provide a reason for “cheer” this holiday season. Published first on TheF |
Mirum Shares Surge More Than 90% in 6 Months: Here's WhyMIRM's lead drug, Livmarli, is driving revenues and the momentum is likely to continue. The company's efforts to build its pipeline beyond Livmarli also hold promise. |
Analysts Are Updating Their Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Estimates After Its Third-Quarter ResultsMirum Pharmaceuticals, Inc. ( NASDAQ:MIRM ) just released its latest third-quarter results and things are looking... |
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver MeetingFOSTER CITY, Calif., November 14, 2024--Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting |
Mirum Pharmaceuticals Third Quarter 2024 Earnings: Beats ExpectationsMirum Pharmaceuticals ( NASDAQ:MIRM ) Third Quarter 2024 Results Key Financial Results Revenue: US$90.4m (up 89% from... |
Mirum Pharmaceuticals Inc (MIRM) Q3 2024 Earnings Call Highlights: Record Sales Surge and ...Mirum Pharmaceuticals Inc (MIRM) reports an 89% increase in net product sales and achieves positive operating cash flow for the first time, while expanding its rare disease pipeline. |